Okyo Pharma Limited ADR (OKYO)

$1.62 0.00 (N/A)
Market Cap 66.92M
Revenue (ttm) 0.00
Net Income (ttm) -4.71M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.06
Volume 17,200
Avg Vol 85,898
Day's Range N/A - N/A
Shares Out 40.56M
Stochastic %K 47%
Beta -0.01
Analysts Strong Sell
Price Target $8.00

Company Profile

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acu...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 20 7495 2379
Address:
14/15 Conduit St, Floor 4, London, United Kingdom
Orlandotrader
Orlandotrader May. 6 at 7:47 PM
$OKYO Knock down that Wall Mr Gorbachev. Need news update to take out that 1.70 level. Let’s Start this Sux Month Trial Already. Stop with the Worthless Presentations.
0 · Reply
Orlandotrader
Orlandotrader May. 5 at 12:59 PM
$OKYO Should be getting Updates on New Trial Recruitment soon as they are Targeting Mid Year Start.
0 · Reply
BillionerOfKing
BillionerOfKing May. 1 at 10:42 PM
$OKYO Current Stock Price: $1.65
0 · Reply
jpurr
jpurr Apr. 28 at 8:58 PM
$OKYO The Gabe factor at play here?
1 · Reply
Orlandotrader
Orlandotrader Apr. 22 at 3:34 PM
$OKYO Hello management any one home?
0 · Reply
Oscarca
Oscarca Apr. 13 at 9:45 AM
$OKYO What are you guys thinking, PRs this week or not ?
1 · Reply
Oscarca
Oscarca Apr. 10 at 1:34 PM
$OKYO Hoping for some PRs next week after the ASCRS presentation tomorrow 🙏🏼
1 · Reply
focafoca99
focafoca99 Apr. 7 at 9:10 PM
$OKYO will hold a scientific advisory board meeting during ASCRS and present urcosimod data there.
0 · Reply
Oscarca
Oscarca Apr. 1 at 8:48 AM
$OKYO It is confirmed that the trials will start in June but no news on where and how to apply yet. Would assume this phase 2b/3 study would pop up on http://clinicaltrials.gov at anytime now..
0 · Reply
Oscarca
Oscarca Mar. 31 at 8:15 AM
$OKYO Robert J. Dempsey the new ceo commercialized two of the biggest blockbuster eye drops ”Restasis” and ”Xiidra” both which has reached over a billion dollars in annually revenue. Then you have the new Chief Medical Officer Flavio Mantelli who commercialized the eye drop medication ”Oxervate” which also generates close to a billon dollars. The team/roster/squad that OKYO has is just insanely strong and insiders owning 32% of the company where as the founder owns 29% which is quite high for a small biotech company.
1 · Reply
Latest News on OKYO
OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May

Apr 29, 2026, 7:00 AM EDT - 14 days ago

OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May

OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting

Apr 7, 2026, 7:00 AM EDT - 5 weeks ago

OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting

OKYO Pharma Announces Chairman and Founder Acquires Shares

Mar 19, 2026, 12:00 PM EDT - 7 weeks ago

OKYO Pharma Announces Chairman and Founder Acquires Shares

Okyo Pharma director John Brancaccio acquires 5,000 shares

2026-03-19T14:15:16.000Z - 7 weeks ago

Okyo Pharma director John Brancaccio acquires 5,000 shares

OKYO Pharma Announces Director Acquires Shares

Mar 19, 2026, 10:00 AM EDT - 7 weeks ago

OKYO Pharma Announces Director Acquires Shares

Okyo Pharma CDO, director acquire shares

2026-03-19T11:37:09.000Z - 7 weeks ago

Okyo Pharma CDO, director acquire shares

OKYO Pharma Announces Chief Development Officer and Director Acquires Shares

Mar 19, 2026, 7:00 AM EDT - 7 weeks ago

OKYO Pharma Announces Chief Development Officer and Director Acquires Shares

Okyo Pharma reports results from Phase 2a trial of urcosimod

2026-03-18T11:22:52.000Z - 2 months ago

Okyo Pharma reports results from Phase 2a trial of urcosimod

OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain

Mar 18, 2026, 7:00 AM EDT - 2 months ago

OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain

OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress

Feb 23, 2026, 11:00 AM EST - 2 months ago

OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress

Okyo Pharma initiated with an Overweight at Piper Sandler

2026-02-20T10:12:28.000Z - 2 months ago

Okyo Pharma initiated with an Overweight at Piper Sandler

OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares

Feb 12, 2026, 10:20 PM EST - 3 months ago

OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares

Okyo Pharma $20M Spot Secondary; price range $1.80-$1.90

2026-02-12T22:20:33.000Z - 3 months ago

Okyo Pharma $20M Spot Secondary; price range $1.80-$1.90

Okyo Pharma announces ordinary shares offering, no amount given

2026-02-12T21:06:40.000Z - 3 months ago

Okyo Pharma announces ordinary shares offering, no amount given

OKYO Pharma Announces Public Offering of Ordinary Shares

Feb 12, 2026, 4:01 PM EST - 3 months ago

OKYO Pharma Announces Public Offering of Ordinary Shares

OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners

Feb 11, 2026, 10:09 AM EST - 3 months ago

OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners

Okyo Pharma appoints Mantelli as Chief Medical Officer

2026-02-10T13:16:08.000Z - 3 months ago

Okyo Pharma appoints Mantelli as Chief Medical Officer

OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer

Feb 10, 2026, 8:00 AM EST - 3 months ago

OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer

OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting

Jan 30, 2026, 11:30 AM EST - 3 months ago

OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting

Okyo Pharma announces highlights from Type C meeting with FDA on urcosimod

2026-01-28T12:45:43.000Z - 3 months ago

Okyo Pharma announces highlights from Type C meeting with FDA on urcosimod

OKYO Pharma Announces Successful Type C Meeting with the FDA

Jan 28, 2026, 7:40 AM EST - 3 months ago

OKYO Pharma Announces Successful Type C Meeting with the FDA

Okyo announces FDA authorized single-patient expanded IND for urcosimod

2026-01-23T12:11:12.000Z - 3 months ago

Okyo announces FDA authorized single-patient expanded IND for urcosimod

FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain

Jan 23, 2026, 7:00 AM EST - 3 months ago

FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain

Okyo Pharma appoints Robery Dempsey as CEO

2026-01-05T12:21:22.000Z - 4 months ago

Okyo Pharma appoints Robery Dempsey as CEO

OKYO Pharma to Ring the Opening Bell at Nasdaq

Dec 19, 2025, 7:00 AM EST - 5 months ago

OKYO Pharma to Ring the Opening Bell at Nasdaq

Okyo Pharma chairman acquires 24,551 company shares

2025-12-15T13:35:29.000Z - 5 months ago

Okyo Pharma chairman acquires 24,551 company shares

Okyo Pharma’s urcosimod shows favorable corneal nerve outcomes in Phase 2 trial

2025-12-11T13:41:22.000Z - 5 months ago

Okyo Pharma’s urcosimod shows favorable corneal nerve outcomes in Phase 2 trial

Okyo Pharma initiated with a Buy at B. Riley

2025-12-08T11:05:40.000Z - 5 months ago

Okyo Pharma initiated with a Buy at B. Riley

Okyo Pharma chairman acquires 27,051 company shares

2025-12-03T12:05:51.000Z - 5 months ago

Okyo Pharma chairman acquires 27,051 company shares

Okyo Pharma chairman acquires 82,018 company shares

2025-11-21T13:36:19.000Z - 6 months ago

Okyo Pharma chairman acquires 82,018 company shares

OKYO Pharma to Present at OIS XV in San Diego

Nov 18, 2025, 8:30 AM EST - 6 months ago

OKYO Pharma to Present at OIS XV in San Diego

Okyo Pharma chairman acquires 210,000 company shares

2025-10-16T12:35:39.000Z - 7 months ago

Okyo Pharma chairman acquires 210,000 company shares

Okyo Pharma announces plans for next stage of development for urcosimod

2025-09-22T12:40:25.000Z - 8 months ago

Okyo Pharma announces plans for next stage of development for urcosimod

OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain

Sep 22, 2025, 8:30 AM EDT - 8 months ago

OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain

Okyo Pharma initiated with a Buy at Lucid Capital

2025-07-31T10:26:14.000Z - 10 months ago

Okyo Pharma initiated with a Buy at Lucid Capital

Okyo Pharma receives $1.9M in non-dilutive funding

2025-07-17T13:16:10.000Z - 10 months ago

Okyo Pharma receives $1.9M in non-dilutive funding

Okyo Pharma reports Phase 2 clinical trial results for urcosimod

2025-07-16T13:25:17.000Z - 10 months ago

Okyo Pharma reports Phase 2 clinical trial results for urcosimod

OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain

Jul 16, 2025, 9:21 AM EDT - 10 months ago

OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain

Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited

Jun 11, 2025, 10:05 AM EDT - 1 year ago

Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited

OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit

May 19, 2025, 7:00 AM EDT - 1 year ago

OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit

OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain

Apr 30, 2025, 7:00 AM EDT - 1 year ago

OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain

OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod

Mar 31, 2025, 8:00 AM EDT - 1 year ago

OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod

OKYO Pharma Announces Chairman and CEO Acquire Shares

Jan 31, 2025, 7:00 AM EST - 1 year ago

OKYO Pharma Announces Chairman and CEO Acquire Shares

Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited

Jan 30, 2025, 9:45 AM EST - 1 year ago

Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited

MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nov 15, 2024, 9:00 AM EST - 1 year ago

MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

MUSQ

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

Oct 23, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Aug 23, 2024, 9:00 AM EDT - 1 year ago

OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

SMXT

OKYO Pharma CEO Interview to Air on Bloomberg TV

Aug 23, 2024, 9:00 AM EDT - 1 year ago

OKYO Pharma CEO Interview to Air on Bloomberg TV

OKYO Pharma Announces Chairman Acquires Shares

Aug 23, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma Announces Chairman Acquires Shares

OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 15, 2024, 12:13 PM EDT - 1 year ago

OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use

Aug 6, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use

OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101

Jul 11, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101

OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease

Jul 10, 2024, 7:00 AM EDT - 2 years ago

OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)

Apr 30, 2024, 7:00 AM EDT - 2 years ago

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)

OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024

Apr 8, 2024, 7:00 PM EDT - 2 years ago

OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery

Apr 2, 2024, 7:00 AM EDT - 2 years ago

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

Mar 22, 2024, 7:00 AM EDT - 2 years ago

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial

Mar 21, 2024, 7:00 AM EDT - 2 years ago

OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial

OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event

Mar 20, 2024, 7:00 AM EDT - 2 years ago

OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event

OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

Feb 9, 2024, 7:00 AM EST - 2 years ago

OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024

Jan 5, 2024, 9:30 AM EST - 2 years ago

OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024

OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)

Oct 9, 2023, 7:00 AM EDT - 2 years ago

OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)

OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares

Sep 15, 2023, 7:00 AM EDT - 2 years ago

OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares

OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares

Sep 14, 2023, 9:15 AM EDT - 2 years ago

OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares

OKYO Pharma Limited Announces Withdrawal of Public Offering

Sep 14, 2023, 8:45 AM EDT - 2 years ago

OKYO Pharma Limited Announces Withdrawal of Public Offering

OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease

Sep 8, 2023, 7:00 AM EDT - 2 years ago

OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease

OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”)

Aug 30, 2023, 7:00 AM EDT - 2 years ago

OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”)

OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023

Aug 15, 2023, 9:00 AM EDT - 2 years ago

OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023

OKYO Pharma Announces Proposed Public Offering of Ordinary Shares

Jul 28, 2023, 5:25 PM EDT - 3 years ago

OKYO Pharma Announces Proposed Public Offering of Ordinary Shares

OKYO Pharma Limited Receives Nasdaq Deficiency Notice

Jul 28, 2023, 5:05 PM EDT - 3 years ago

OKYO Pharma Limited Receives Nasdaq Deficiency Notice

Orlandotrader
Orlandotrader May. 6 at 7:47 PM
$OKYO Knock down that Wall Mr Gorbachev. Need news update to take out that 1.70 level. Let’s Start this Sux Month Trial Already. Stop with the Worthless Presentations.
0 · Reply
Orlandotrader
Orlandotrader May. 5 at 12:59 PM
$OKYO Should be getting Updates on New Trial Recruitment soon as they are Targeting Mid Year Start.
0 · Reply
BillionerOfKing
BillionerOfKing May. 1 at 10:42 PM
$OKYO Current Stock Price: $1.65
0 · Reply
jpurr
jpurr Apr. 28 at 8:58 PM
$OKYO The Gabe factor at play here?
1 · Reply
Orlandotrader
Orlandotrader Apr. 22 at 3:34 PM
$OKYO Hello management any one home?
0 · Reply
Oscarca
Oscarca Apr. 13 at 9:45 AM
$OKYO What are you guys thinking, PRs this week or not ?
1 · Reply
Oscarca
Oscarca Apr. 10 at 1:34 PM
$OKYO Hoping for some PRs next week after the ASCRS presentation tomorrow 🙏🏼
1 · Reply
focafoca99
focafoca99 Apr. 7 at 9:10 PM
$OKYO will hold a scientific advisory board meeting during ASCRS and present urcosimod data there.
0 · Reply
Oscarca
Oscarca Apr. 1 at 8:48 AM
$OKYO It is confirmed that the trials will start in June but no news on where and how to apply yet. Would assume this phase 2b/3 study would pop up on http://clinicaltrials.gov at anytime now..
0 · Reply
Oscarca
Oscarca Mar. 31 at 8:15 AM
$OKYO Robert J. Dempsey the new ceo commercialized two of the biggest blockbuster eye drops ”Restasis” and ”Xiidra” both which has reached over a billion dollars in annually revenue. Then you have the new Chief Medical Officer Flavio Mantelli who commercialized the eye drop medication ”Oxervate” which also generates close to a billon dollars. The team/roster/squad that OKYO has is just insanely strong and insiders owning 32% of the company where as the founder owns 29% which is quite high for a small biotech company.
1 · Reply
aletz
aletz Mar. 30 at 10:12 AM
$OKYO https://www.biostockinfo.com/biotech-catalyst-ai-scanner-april-wk1/
1 · Reply
Oscarca
Oscarca Mar. 24 at 9:07 PM
$OKYO one of the brains behind urcosimod Pedram Hamrah being named in the top 50 list for most influential ophthalmologist in the world.
0 · Reply
Oscarca
Oscarca Mar. 24 at 1:27 PM
$OKYO patiently waiting for phase 2b/3 study enrollment news. If they are starting trials in June it feels like news should come out at any given time about facilities, locations, enrollment number, criteria’s etc.
2 · Reply
Orlandotrader
Orlandotrader Mar. 19 at 2:32 PM
$OKYO John Brancaccio, Non-Executive Director, has acquired 5,000 of the Company’s ordinary shares on NASDAQ at $1.61, bringing his total holding to 31,201 shares.
0 · Reply
DARKP00L
DARKP00L Mar. 19 at 2:23 PM
$OKYO 10:06 on Mar. 19 2026 OKYO Pharma Director John Brancaccio Buys 5,000 Shares At An Average Price Of $1.61, Raising Total Holdings to 31,201 #tradeideas
0 · Reply
DARKP00L
DARKP00L Mar. 19 at 11:20 AM
$OKYO 07:13 on Mar. 19 2026 OKYO Pharma Executive Buys More Shares, Signals Confidence #tradeideas
0 · Reply
BioTuesdays
BioTuesdays Mar. 18 at 4:33 PM
$OKYO has announced new positive findings from an exploratory analysis of patient-reported outcomes in its recently completed Phase 2a trial of urcosimod for the treatment of neuropathic corneal pain (NCP). https://biotuesdays.com/2026/03/18/okyo-reports-new-phase-2-data-for-urcosimod-in-ncp/
0 · Reply
DARKP00L
DARKP00L Mar. 18 at 11:20 AM
$OKYO 07:10 on Mar. 18 2026 OKYO Pharma Reports Trial Results For Eye Pain Treatment #tradeideas
0 · Reply
MrTicker
MrTicker Mar. 18 at 11:14 AM
$OKYO OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain GLOBENEWSWIRE 6:00 AM ET 3/18/2026
0 · Reply
DARKP00L
DARKP00L Mar. 18 at 11:11 AM
$OKYO 07:10 on Mar. 18 2026 OKYO Pharma Reports Trial Results For Eye Pain Treatment #tradeideas
0 · Reply
rp6577
rp6577 Mar. 18 at 11:05 AM
$OKYO https://x.com/okyopharma/status/2034223289581908257?s=46&t=ca2qCrnqXP8cBaayMxMU6g $XBI
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 14 at 2:32 AM
$OKYO RSI: 45.45, MACD: -0.0842 Vol: 0.03, MA20: 1.71, MA50: 2.03 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply